Abstract
INTRODUCTION: One of the major causes of mortality in chronic kidney disease (CKD) patients on hemodialysis is premature atherosclerosis. Selenium, a trace element involved in important enzymatic activities inside the body, has protective effects against lipid oxidation and inhibits cholesterol accumulation in blood vessels. OBJECTIVES: To determine the effect of selenium supplementation on lipid profile in hemodialysis patients. PATIENTS AND METHODS: In this double-blinded randomized clinical trial which lasted for 3 months, 84 hemodialysis patients with selenium deficiency were divided into experimental group (received selenium supplementation) or control group (received placebo). Total cholesterol, low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), blood urea nitrogen (BUN), creatinine, and selenium level were measured before and after the study. RESULTS: Mean (±SD) serum LDL-C level significantly increased in experimental group from 85.66 (±31.12) to 109.12 (±32.29) mg/dl (P<0.001). Likewise, in control group serum LDL-C significantly increased from 80.55 (±21.13) to 97.05 (±28.07) mg/dl (P<0.001). However, with control of LDL-C effect before and after the study, it was revealed that LDL-C change was not statistically significant (P=0.21). Similarly, total cholesterol and triglyceride levels did not show significant changes before and after the study in any group. CONCLUSION: Selenium supplementation had no beneficial effect on lipid profile in hemodialysis patients.